Latest News & Features
Big Pharma
Appeals court sides with GSK unit in licensing dispute over ovarian cancer drug | Judges find fault with previous decision ordering the pharma firm to pay royalties on all sales of an ovarian cancer treatment. 13 February 2024
article
PhRMA says controversial draft framework misinterprets the Bayh-Dole Act and could undo years of success | FTC unanimously supports the proposal. 8 February 2024
Americas
Senator criticises patent thickets and ‘monopolies’ ahead of senate hearing convened to interrogate CEOs | Sales of MSD’s blockbuster cancer treatment Keytruda rival McDonald’s annual revenue, says report. 8 February 2024
Biotechnology
Biotech claims action was necessary due to unfavourable rulings after being targeted by a rival | Accuses gene technology firm of attempting to shrink the competitive landscape for different spatial biology platforms. 6 February 2024
Big Pharma
Oncology specialist seeks to block another bendamustine generic following trio of lawsuits in January | Firm filed complaint for patent infringement against Dr Reddy’s. 6 February 2024
Americas
Firm adds to its New York office with the appointment of ANDA expert as a partner in litigation group | Represented clients such as Gilead, Sanofi-Aventis, and Bristol-Myers Squibb in high-stakes cases. 1 February 2024
Big Pharma
PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation. 1 February 2024
Americas
Pharma giants raise concerns about Moderna’s COVID-19 vaccine patents | Company's statements to the FDA and PTAB contain "inconsistencies" | Appeals Board urged to scrutinise assertions. 1 February 2024
Biotechnology
MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body. 30 January 2024
Medtech
Biotech firm CareDx found to have infringed one of two patents-in-suit through sale of AlloSure and AlloSeq | Damages award consists of $83.6m in lost profits and $12.6m in royalties. 30 January 2024